Prenatal Test for Fetal Aneuploidy Detection
- Conditions
- AneuploidyTrisomy 21
- Registration Number
- NCT01256606
- Lead Sponsor
- Roche Sequencing Solutions
- Brief Summary
The purpose of this study is to develop and evaluate a blood test for pregnant women for detection of fetal aneuploidy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 4000
- Subject is 18yrs or older
- Subject has a singleton pregnancy
- Subject is planning to undergo chorionic villus sampling (CVS) and/or amniocentesis with current pregnancy
- Subject is able to provide consent
- Subject is pregnant with more than one fetus
- Subject (mother) has known aneuploidy
- Subject has active malignancy requiring major surgery or systemic chemotherapy or has a history of metastatic cancer.
- Subject has already undergone CVS or amniocentesis during current pregnancy prior to study enrollment.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of blood test to results from chorionic villus sampling or amniocentesis for fetal aneuploidy detection 24 months Circulating genomic material from maternal blood will be quantified using biochemical techniques to determine the presence of fetal aneuploidy. The results obtained from analysis of circulating genomic material will be compared to the karyotype results from chorionic villus sampling or amniocentesis.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
Prenatal Diagnosis of Northern California
πΊπΈSacramento, California, United States
East Bay Perinatal Medical Associates
πΊπΈOakland, California, United States
University of California - San Diego
πΊπΈSan Diego, California, United States
University of California - San Francisco
πΊπΈSan Francisco, California, United States
Atlanta Perinatal Consultants
πΊπΈAtlanta, Georgia, United States
Medical College of Wisconsin
πΊπΈMilwaukee, Wisconsin, United States